Could This Stock Be the Next Biotech Buyout?
The biotechnology industry is getting more attention than usual following a buyout offer for Alpine Immune Sciences (NASDAQ: ALPN) from Vertex Pharmaceuticals (NASDAQ: VRTX).
Vertex recently offered Alpine Immune Sciences $65 per share, or about $4.9 billion in cash. On April 9, the day before the announcement, Alpine's stock price closed at about $39 per share.
Government regulators rarely try to prevent big pharmaceutical companies from acquiring clinical-stage biotechs. This means Alpine shareholders will most likely see their investment increase by about 67% when the deal closes, probably in a couple of months.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
452,70 €
-3,26 %
Vertex Pharmaceuticals Inc. ist ein klarer Community-Favorit mit mehr Buy- als Sell-Einschätzungen.
Trotz eines Kursziels von 440 €, das unter 452.7 € liegt, ergibt sich für Vertex Pharmaceuticals Inc. ein negatives Potenzial von -2.81%.
